Видео ютуба по тегу Erdafitinib

Erdafitinib for bladder cancer: more to come following FDA approval
Erdafitinib for bladder cancer: more to come following FDA approval
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
NORSE: erdafitinib and cetrelimab in metastatic urothelial cancer
NORSE: erdafitinib and cetrelimab in metastatic urothelial cancer
The role of erdafitinib in treating patients with bladder cancer
The role of erdafitinib in treating patients with bladder cancer
The future role of erdafitinib in advanced urothelial carcinoma
The future role of erdafitinib in advanced urothelial carcinoma
Erdafitinib: one more tool for bladder cancer
Erdafitinib: one more tool for bladder cancer
An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinoma
An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinoma
Dr. Siefker-Radtke on Next Steps With Erdafitinib in Bladder Cancer
Dr. Siefker-Radtke on Next Steps With Erdafitinib in Bladder Cancer
Important Side Effects with Erdafitinib & T DXd
Important Side Effects with Erdafitinib & T DXd
Erdafitinib and enfortumab vedotin in pretreated FGFR2/3-mutant bladder cancer
Erdafitinib and enfortumab vedotin in pretreated FGFR2/3-mutant bladder cancer
THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations
THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations
Update on Erdafitinib, a Treatment for Metastatic Urothelial Cancer with Dr. Siefker-Radtke
Update on Erdafitinib, a Treatment for Metastatic Urothelial Cancer with Dr. Siefker-Radtke
Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations
Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations
Erdafitinib +/- cetrelimab in mUC patients with FGFR alterations
Erdafitinib +/- cetrelimab in mUC patients with FGFR alterations
The future of the TAR-210 delivery system for erdafitinib in NMBIC
The future of the TAR-210 delivery system for erdafitinib in NMBIC
Dr. Siefker-Radtke on the Phase II Study of Erdafitinib in Patients With Urothelial Carcinoma
Dr. Siefker-Radtke on the Phase II Study of Erdafitinib in Patients With Urothelial Carcinoma
Arlene Siefker-Radtke, MD, regarding the development of erdafitinib in bladder cancer
Arlene Siefker-Radtke, MD, regarding the development of erdafitinib in bladder cancer
Safety and efficacy of the erdafitinib intravesical delivery system: Phase 1: first-in-human study
Safety and efficacy of the erdafitinib intravesical delivery system: Phase 1: first-in-human study
ASCO 2023 Highlights on erdafitinib in metastatic urothelial cancer with select FGFR alterations
ASCO 2023 Highlights on erdafitinib in metastatic urothelial cancer with select FGFR alterations
Phase III THOR study: erdafitinib vs. pembrolizumab in FGFR-altered advanced or metastatic UC
Phase III THOR study: erdafitinib vs. pembrolizumab in FGFR-altered advanced or metastatic UC